Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jerome Yaklic

Obstetrics & Gynecology Galveston, TX Medical Doctor

NPI 1235164476 CMS profile 1110320

1005 Harborside Drive, Galveston, TX 77555

Open in the dashboard

General payments

$35,191

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$380,452 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jerome Yaklic of Galveston, TX is reported in the CMS Open Payments database as having received $35,191 across 77 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $380,452 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $120 2
2024 General $574 8
2023 General $166 5
2022 General $1,241 8
2021 General $126 2
2020 General $1,412 3
2019 General $31,552 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerome Yaklic
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Jerome Yaklic were reported at $120. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Jerome Yaklic Obstetrics & Gynecology median Middle half National median
2019 $31,552 $172 $62–$391 $163
2020 $1,412 $94 $36–$222 $114
2021 $126 $136 $42–$369 $132
2022 $1,241 $160 $50–$433 $149
2023 $166 $169 $56–$423 $160
2024 $574 $152 $50–$371 $164
2025 $120 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $27,770 37 payments
  2. Medtronic USA, Inc. $2,665 8 payments
  3. Merck Sharp & Dohme Corporation $2,420 4 payments
  4. Medtronic, Inc. $1,249 10 payments
  5. Boston Scientific Corporation $760 8 payments
  6. CooperSurgical, Inc. $100 2 payments
  7. Allergan Inc. $80 1 payment
  8. Organon LLC $44 3 payments
  9. Applied Medical Resources Corporation $37 1 payment
  10. Axonics Modulation Technologies, Inc. $37 1 payment
  11. Other $28 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29,915 12 payments
  2. Food and Beverage $2,822 51 payments
  3. Travel and Lodging $2,454 14 payments
Products named General payments · program years 2019–2025
  1. Orilissa $27,770 37 payments
  2. INTERSTIM Sacral Nerve Stimulation $2,665 8 payments
  3. NEXPLANON $2,420 4 payments
  4. Solyx SIS System $268 3 payments
  5. INTERSTIM Sacral Nerve Stimulation $189 4 payments
  6. Advantage System $138 1 payment
  7. SOLYX $110 1 payment
  8. Endo Stitch $93 1 payment
  9. BOTOX $80 1 payment
  10. Axonics $64 2 payments
  11. Other $181 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

158

Median for Obstetrics & Gynecology: 65

Drug cost

$30,016

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

80.4%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 30 $15,060
Gemtesa Vibegron Brand 13 $8,957
Trospium Chloride Er Trospium Chloride Brand 14 $3,345
Trospium Chloride Generic 15 $897
Estradiol Generic 16 $830
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 22 $481
Oxybutynin Chloride Er Oxybutynin Chloride Brand 21 $386
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 27 $60

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$10,963

Medicare's payments for the services billed

Medicare patients

49

Average age 73

Services billed

101

49 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record